抗狂犬病病毒单克隆抗体研究进展

Advances in monoclonal antibodies against rabies virus

狂犬病作为一种可防不可治的烈性传染病,采取有效的暴露后处置措施至关重要。当人处于狂犬病Ⅲ级暴露下,接种狂犬病免疫球蛋白(rabies immunoglobulin,RIG)是暴露后处置中的重要环节。源于人或动物血浆的RIG存在产能不足、价格偏高等问题,选择有效的抗狂犬病病毒单克隆抗体代替RIG成为一种趋势。作为WHO推荐的、替代RIG的被动免疫制剂,抗狂犬病病毒单克隆抗体具有适应性强、安全性高等优点。鉴于此,本研究拟对已上市的和正在研发的抗狂犬病病毒单克隆抗体进行综述,为该领域的后续研发提供参考和借鉴。

Rabies is a vaccine-preventable fulminating infectious disease without effective treatment.Therefore,effective rabies post-exposure prophylaxis becomes more important.Vaccination of rabies immunoglobulin(RIG)is an essential post-exposure treatment after gradeⅢexposure to rabies.At present,insufficient production and high price of RIG derived from human or animal plasma make choosing effective anti-rabies monoclonal antibodies to replace RIG become a trend.As a passive immune agent recommended by WHO to replace RIG,rabies monoclonal antibodies have the advantages of strong adaptability and high safety.In view of this,this paper will review marketed and being developed monoclonal antibodies against rabies virus and provide reference for further research on monoclonal antibodies against rabies virus.